Mark Ballow1. 1. Division of Allergy and Immunology, Women & Children's Hospital of Buffalo and SUNY Buffalo, School of Medicine, Buffalo, New York; Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, Children's Research Institute, St. Petersburg, Florida. Electronic address: ballow@buffalo.edu.
Abstract
OBJECTIVE: To review the literature related to the identification and treatment of secondary complications associated with common variable immunodeficiency (CVID). DATA SOURCES: The databases of PubMed and Ovid MEDLINE were searched for articles pertaining to comorbid conditions occurring in patients with CVID and effective treatment for or management of those conditions. STUDY SELECTIONS: Articles were selected based on their relevance to the focus of this review, with an emphasis on clinical phenotypes and biomarkers that can help identify patients with CVID and a secondary complication and issues related to their clinical management. RESULTS: Noninfective complications have generated a better understanding of the pathogenesis and treatment of CVID by helping to define clinical and immunologic phenotypes of this disease. These clinical phenotypes have been correlated with different survival risks. CONCLUSION: Emerging and ongoing research on clinical phenotypes and biomarkers of CVID may help identify and better target treatment for patients with CVID who will develop secondary complications. It is hoped that through this improved knowledge of outcomes, more appropriate treatment for patients can be targeted.
OBJECTIVE: To review the literature related to the identification and treatment of secondary complications associated with common variable immunodeficiency (CVID). DATA SOURCES: The databases of PubMed and Ovid MEDLINE were searched for articles pertaining to comorbid conditions occurring in patients with CVID and effective treatment for or management of those conditions. STUDY SELECTIONS: Articles were selected based on their relevance to the focus of this review, with an emphasis on clinical phenotypes and biomarkers that can help identify patients with CVID and a secondary complication and issues related to their clinical management. RESULTS: Noninfective complications have generated a better understanding of the pathogenesis and treatment of CVID by helping to define clinical and immunologic phenotypes of this disease. These clinical phenotypes have been correlated with different survival risks. CONCLUSION: Emerging and ongoing research on clinical phenotypes and biomarkers of CVID may help identify and better target treatment for patients with CVID who will develop secondary complications. It is hoped that through this improved knowledge of outcomes, more appropriate treatment for patients can be targeted.
Authors: C Bethune; W Egner; T Garcez; A Huissoon; S Jolles; Y Karim; R Jain; S Savic; K Kelley; D Grosse-Kreul; S Grigoriadou Journal: Clin Exp Immunol Date: 2019-03-07 Impact factor: 4.330